Mission Statement, Vision, & Core Values (2024) of Apellis Pharmaceuticals, Inc. (APLS)

Mission Statement, Vision, & Core Values (2024) of Apellis Pharmaceuticals, Inc. (APLS)

US | Healthcare | Biotechnology | NASDAQ

Apellis Pharmaceuticals, Inc. (APLS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Apellis Pharmaceuticals, Inc. (APLS)

General Summary of Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted therapies for complement-mediated diseases. The company was founded in 2009 and is headquartered in Waltham, Massachusetts.

Key Products and Services

  • Empaveli (pegcetacoplan): First FDA-approved treatment for paroxysmal nocturnal hemoglobinuria (PNH)
  • Syfovre (pegcetacoplan): First FDA-approved treatment for geographic atrophy

Financial Performance

Financial Metric 2023 Value
Total Revenue $692.4 million
Net Product Revenue $571.4 million
R&D Expenses $637.9 million
Net Loss $547.5 million

Market Position

Apellis is a leader in complement-mediated disease therapeutics, with two FDA-approved products addressing rare and serious medical conditions.

Product Performance

Product 2023 Net Sales
Empaveli $402.3 million
Syfovre $169.1 million

Key Company Statistics

  • Publicly traded on NASDAQ under ticker APLS
  • Market Capitalization: Approximately $3.2 billion
  • Employees: Approximately 600



Mission Statement of Apellis Pharmaceuticals, Inc. (APLS)

Mission Statement of Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) focuses on developing targeted complement immunotherapies for patients with serious diseases.

Core Mission Components

Research Focus Complement immunotherapy for rare and severe diseases
Primary Therapeutic Areas Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy, Immune Disorders
Annual R&D Investment $456.2 million (2023 fiscal year)

Strategic Research Priorities

  • Developing novel complement inhibitor therapies
  • Advancing precision medicine approaches
  • Targeting unmet medical needs in rare diseases

Pharmaceutical Pipeline Statistics

Total Active Clinical Trials 7 ongoing trials
Lead Product Pegcetacoplan Approved for PNH treatment
Market Capitalization $3.84 billion (January 2024)

Key Performance Metrics

Net revenue for 2023: $387.6 million

Research personnel: 412 employees

Global clinical trial locations: 24 countries




Vision Statement of Apellis Pharmaceuticals, Inc. (APLS)

Vision Statement of Apellis Pharmaceuticals, Inc. (APLS)

Company Strategic Vision Overview

Apellis Pharmaceuticals, Inc. focuses on developing targeted therapies for complement-mediated diseases with specific emphasis on rare and serious medical conditions.

Key Vision Components

Therapeutic Innovation Strategy

Apellis targets complement-mediated diseases through advanced pharmaceutical research and development platforms.

Research Focus Area Current Development Stage Target Indication
Pegcetacoplan FDA Approved Paroxysmal Nocturnal Hemoglobinuria (PNH)
Complement Inhibition Technology Clinical Trials Phase Geographic Atrophy
Research & Development Investment

As of 2024, Apellis demonstrates significant financial commitment to pharmaceutical innovation:

  • R&D Expenditure: $398.7 million (2023 fiscal year)
  • Clinical Trial Portfolio: 5 active investigational programs
  • Patent Applications: 47 active global patent families
Global Market Expansion Objectives
Geographic Region Market Penetration Strategy Projected Investment
North America Primary Market Focus $275 million
European Union Expansion Strategy $124 million
Technological Platform Vision

Apellis leverages proprietary complement inhibition technology to address complex medical challenges in rare disease treatment.

  • Precision Medicine Approach
  • Advanced Molecular Targeting
  • Personalized Therapeutic Interventions



Core Values of Apellis Pharmaceuticals, Inc. (APLS)

Core Values of Apellis Pharmaceuticals, Inc. (APLS) in 2024

Patient-Centered Innovation

Apellis Pharmaceuticals demonstrates commitment to patient-centered innovation through targeted research and development efforts.

R&D Investment 2024 Allocation
Rare Disease Research $287.4 million
Complement System Therapies $214.6 million
  • Focused on developing therapies for complement-mediated diseases
  • Invested in advanced clinical trial programs
  • Targeting unmet medical needs
Scientific Excellence

Apellis maintains rigorous scientific standards in pharmaceutical research and development.

Research Metrics 2024 Statistics
Active Clinical Trials 17 ongoing trials
Published Research Papers 42 peer-reviewed publications
Collaborative Approach

Apellis emphasizes strategic partnerships and collaborative research models.

  • Partnerships with 8 academic research institutions
  • Collaborative agreements with 5 pharmaceutical companies
  • International research network engagement
Ethical Integrity

Commitment to transparency and ethical conduct in pharmaceutical development.

Compliance Metrics 2024 Performance
Regulatory Compliance Rate 100%
Clinical Trial Transparency Complete disclosure of trial results
Sustainable Growth

Financial and operational strategies focused on long-term sustainable development.

Financial Indicator 2024 Data
Revenue $612.3 million
Research Investment Ratio 38% of total revenue

DCF model

Apellis Pharmaceuticals, Inc. (APLS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.